LifeArc monetises Keytruda® (pembrolizumab) royalty interests to fund further research and investment

LifeArc, a UK-based medical research charity, has received US$1.297 billion from CPPIB Credit Europe S.à r.l. - a wholly owned subsidiary of Canada Pension Plan Investment Board (CPPIB) - for a portion of its royalty interest in Keytruda®* (pembrolizumab), MSD’s anti-PD-1 therapy. LifeArc secured rights to royalties from pembrolizumab as a result of the charity’s 2007 collaboration to humanise the antibody-based therapy now marketed by MSD.

Video of the week | The Guardian | CrisprCas9 explained

Professor Jennifer Doudna, one the pioneers of Crispr-Cas9 gene editing explains how this important discovery enables precise changes to our DNA , which can be used to correct mutations that cause genetic disease and completely eradicate it from a germline. Doudna raises the 4 key issues of debate around this revolutionary discovery and suggests what will have the most immediate impact.

Lonza chooses Synpromics’ novel inducible promoter platform to manufacture biopharmaceuticals

Synpromics Ltd, the leader in gene control, and Lonza Pharma & Biotech announce a partnership for the commercialisation of a number of inducible promoters to improve the manufacturing of biopharmaceuticals. The commercial agreement with Lonza follows the award of an Innovate UK grant to Synpromics announced on 23 April 2018. Lonza and Synpromics worked together to develop and test these innovative promoters in Lonza’s industry-leading GS Xceed® Expression System.

Locate Bio receives additional £2.0 million investment from Mercia to expand gene and cell therapy pipeline

Locate Bio Ltd has received an additional £2.0 million of investment from Mercia Technologies PLC and its third party fund, the Midlands Engine Investment Fund to expand the application of its technologies, including its promising gene therapy technology IntraStem™, into new high value therapy areas to both broaden its in-house development pipeline and provide additional partnering opportunities.

F-star expedites its transition to a wholly-owned portfolio strategy

• Reconfigured collaboration represents major advancement in F-star’s pivot to a wholly-owned portfolio strategy • F-star retains lead clinical asset, first-in-class bispecific antibody, FS118 • FS118 Phase 1 trial study continues according to F-star protocol • Merck exercises option for one discovery stage programme and retains option for second discovery programme from original collaboration

CEO Update | Monday 13 May 2019

Today we’ve launched the 2019 State of the Discovery Nation report in conjunction with the Medicines Discovery Catapult. It provides insights into the UK’s growing medicines discovery industry, revealing a thriving service and supply sector for the UK in addition to its R&D biotechs. Research for the report found that service and supply companies account for 80% of SMEs in UK medicines discovery, and 90% of employment.

New report unveils a thriving service and supply sector for UK medicines discovery

New report unveils a thriving service and supply sector for UK medicines discovery Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness Today [13 May 2019], Medicines Discovery Catapult and the BioIndustry Association unveil their 2019 State of the Discovery Nation report, providing new insights into the UK’s growing medicines discovery industry.

BIA | New report unveils a thriving service and supply sector for UK medicines discovery

Driving innovation into state-of-the-art technologies such as Artificial Intelligence and Complex Cell Models is key to maintaining the UK’s global competitiveness

Changes to SME R&D tax credit scheme could harm a thriving sector says BIA

The BioIndustry Association (BIA) is calling for the Government to think again on proposals which could see harmful changes to the way that SMEs are supported through R&D tax credits.

Action Medical Research | Born with a rare disease

Mark and Amanda's son Joshua was born with the rare disease Jeune syndrome. Joshua is now a very happy and lively little two-year-old who, "is continuing to prove everyone wrong," says his proud dad Mark. A baby born with Jeune syndrome will have a tiny bell-shaped ribcage as well as short arms and legs. Sadly they can face many other complications too. Those who survive face the prospect of long-term assisted ventilation and complicated surgeries. Action Medical Research, BIA Charity of the Year 2019, is funding vital research into this rare, hereditary condition with no cure. For more information on the BIA's work on rare diseases, take a look at our Rare Disease Industry Group. Are you interested in joining us as Charity of the Year for 2020?